Special Issue

Drug Targeting towards Fighting Pathogen Bacteria

Message from the Guest Editor

One of the major public health concerns of the 21st century is the continuous emergence of antibioticresistant strains, which cause a serious threat to the efficient prevention and treatment of bacterial-related infections. Antibiotic resistance can be considered an inevitable consequence of the rambunctious and unregulated use of antibiotics, which remains a major factor facilitating the emergence of antibiotics resistance worldwide. Several fields of medicine depend on the availability of antibiotic drugs; for instance, the immunosuppression induced by cancer therapy and long-term vascular catheter placement make cancer patients susceptible to bacterial infections often caused by resistant organisms, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycinresistant enterococci (VRE). Thus, to avoid secondary infections, cancer patients are routinely given antibiotics, which cause many side effects, including antimicrobial resistance. Conventional antibiotics have many disadvantages, such as the development of resistance and, in some cases, a low therapeutic index.

Guest Editor

Dr. Sandra N. Pinto

iBB-Institute for Bioengineering and Biosciences, Associate Laboratory I4HB-Institute for Health and Bioeconomy, Department of Bioengineering, Instituto SuperiorTécnico, Universidade de Lisboa, 1049-001 Lisboa, Portugal

Deadline for manuscript submissions

closed (31 May 2023)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/127822

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

